Epigenetic compound screening platform, including methods and cell lines. In an exemplary screening method, ADK-null, ADK-L, and ADK-S cell lines may be selected. The ADK-null cell line may express no ADK protein. The ADK-L cell line may express only the long (L), nuclear isoform of a mammalian ADK protein from an exogenous construct. The ADK-S cell line may express only the short (S), cytoplasmic isoform of a mammalian ADK protein from an exogenous construct. Each of the cell lines may be exposed to the same test compound. A level of DNA or histone methylation, or DNA or histone methyltransferase activity for each of the exposed cell lines may be measured. The level for each exposed cell line may be compared to a corresponding level measured without exposure to the test compound, to determine whether the test compound affects DNA or histone methylation, or DNA or histone methyltransferase activity, in any of the cell lines.

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

A method for producing ergothioneine or a related substance, where the method includes culturing a microorganism having an ergothioneine biosynthetic gene with an increased adenosine kinase (Adk) activity, and collecting the ergothioneine, a related substance thereof, or a mixture thereof from the medium obtained by the culture or the bacterial cells.

The present disclosure provides enzymatic methods for the production of 3-phosphate-nucleoside-5-triphosphate (NQP). The present disclosure further provides enzymatic methods for the production of nucleotide-5-triphosphates.

The present invention provides antisense oligonucleotides targeting adenosine kinase. Such antisense oligonucleotides are useful in treatment of a range of neurological diseases, such as epilepsy. Compositions and methods of treating neurological diseases using the oligonucleotides of the invention are provided.

The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.